Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Yuko Asari"'
Autor:
Shinobu Takayasu, Satoru Mizushiri, Yutaka Watanuki, Satoshi Yamagata, Mari Usutani, Yuki Nakada, Yuko Asari, Shingo Murasawa, Kazunori Kageyama, Makoto Daimon
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Immune checkpoint inhibitors (ICIs) treatment can result in endocrine immune-related adverse events (irAEs), including pituitary dysfunction. Quick diagnosis of secondary adrenal insufficiency (AI) is challenging because no universal definit
Externí odkaz:
https://doaj.org/article/c0fd8f00198140619fcc21afe2473ae2
Autor:
Shingo Murasawa, Kazunori Kageyama, Mari Usutani, Yuko Asari, Noriko Kinoshita, Yuki Nakada, Yutaka Watanuki, Shinobu Takayasu, Makoto Daimon
Publikováno v:
Journal of the Renin-Angiotensin-Aldosterone System. 2023:1-9
Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Unilateral PA can be cured using unilateral adrenalectomy (Adx). PA surgery outcome (PASO) criteria, which include clinical and biochemical outcomes, have been proposed to
Presence of aberrant adrenocorticotropic hormone precursors in two cases of McCune–Albright syndrome
Autor:
Makoto Daimon, Yutaka Oki, Yuko Asari, Yuta Okawa, Koshi Makita, Shinobu Takayasu, Ken Terui, Kazunori Kageyama, Satoshi Yamagata
Publikováno v:
Endocrine Journal. 67:353-359
McCune-Albright syndrome (MAS) is a rare disorder. MAS is classically defined by the occurrence of fibrous dysplasia, café-au-lait skin macules, and precocious puberty. In addition to precocious puberty, other hyperfunctioning endocrinopathies may o
Autor:
Satoshi Yamagata, Koshi Makita, Kazunori Kageyama, Makoto Daimon, Ken Terui, Shinobu Takayasu, Yuko Asari
Publikováno v:
Internal Medicine
Pembrolizumab, or anti-programmed death receptor 1 antibody, is an immune checkpoint inhibitor that can cause immune-related adverse events. We herein report for the first time the progression of hypopituitarism and hypothyroidism after treatment wit
Autor:
Kazunori Kageyama, Ken Terui, Satoshi Yamagata, Yuko Asari, Koshi Makita, Makoto Daimon, Yutaka Oki, Shinobu Takayasu, Yuta Okawa
Publikováno v:
Journal of the Endocrine Society
Background: McCune-Albright syndrome (MAS) is a rare disorder. MAS is caused by an activating postzygotic somatic mutation in the GNAS, and, is classically defined by the occurrence of fibrous dysplasia (FD), café-au-lait skin macules, and precociou
Autor:
Yuko Asari1, Kazunori Kageyama1 kkageyama@hkg.odn.ne.jp, Yuki Nakada1, Mizuki Tasso1, Shinobu Takayasu1, Kanako Niioka1, Noriko Ishigame1, Makoto Daimon1
Publikováno v:
OncoTargets & Therapy. Sep2017, Vol. 10, p4329-4338. 10p.
Publikováno v:
Endocrine journal. 67(2)
Cushing's disease is primarily caused by autonomic hypersecretion of adrenocorticotropic hormone (ACTH) from a pituitary adenoma. In Cushing's disease, mutations in the ubiquitin-specific protease 8 (USP8) have been detected. These mutations are asso
Publikováno v:
Endocrine journal. 66(6)
Cushing's disease is almost always caused by hypersecretion of adrenocorticotropic hormone (ACTH) from a pituitary adenoma. A mutation in the deubiquitinase gene USP8 has been found in human ACTH-producing pituitary adenoma cells. This mutational hot
Autor:
Masamichi Itoga1,2 gacchi88@hotmail.com, Yuko Asari1, Takeshi Morimoto1, Kageaki Taima1, Kunihiko Nakamura1, Hisashi Tanaka1, Shingo Takanashi1,3, Hiroyuki Kayaba1, Ken Okumura1, Yoshihito Tanaka1
Publikováno v:
BMC Research Notes. 2015, Vol. 8 Issue 1, p1-5. 5p. 1 Color Photograph, 1 Black and White Photograph, 1 Chart.
Autor:
Yasumasa Iwasaki, Noriko Ishigame, Yuki Nakada, Yuko Asari, Kazunori Kageyama, Rie Desaki, Shinobu Takayasu, Kanako Niioka, Aya Sugiyama, Makoto Daimon, Shingo Murasawa
Publikováno v:
Endocrine Journal. 62:1083-1090
Cushing's disease is primarily caused by adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. Pituitary tumor-transforming gene 1 (PTTG1) expression, a hallmark of pituitary tumors, stimulates pituitary cell proliferation. Histone deacety